Physician profile
Meng Hua
NPI 1962502773
$1,626.65
in general payments reported to CMS, 2019-2025
15 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $67.69 · 2021: $142 · 2022: $183 · 2023: $259 · 2024: $551 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.66 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $917.41 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Cvrx, INC. | $142.12 | 2021 | |
| Braintree Laboratories, INC. | $85.65 | 2022-2024 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $84.21 | 2023-2025 | Dupixent |
| Abbvie INC. | $61.61 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $55.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.66 | 2019-2024 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $42.43 | 2019 | |
| Medtronic, INC. | $41.88 | 2025 | Endoflip |
| Takeda Pharmaceuticals U.S.A., INC. | $33.09 | 2024 | Entyvio |
| Pfizer INC. | $32.94 | 2019-2024 | |
| 3b Medical, INC. | $25.77 | 2024 | Luna |
| Jazz Pharmaceuticals INC. | $18.65 | 2024 | |
| Allergan, INC. | $17.18 | 2019 | |
| Novo Nordisk INC | $16.74 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Hua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.